121.40Open121.40Pre Close0 Volume11 Open Interest170.00Strike Price0.00Turnover69.40%IV20.28%PremiumJan 17, 2025Expiry Date72.26Intrinsic Value100Multiplier25DDays to Expiry49.14Extrinsic Value100Contract SizeAmericanOptions Type0.9804Delta0.0011Gamma3.31Leverage Ratio-0.0605Theta0.1121Rho3.25Eff Leverage0.0301Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet